Acute Myeloid Leukemia
The latest news, research, and perspectives in acute myeloid leukemia (AML). AML, an aggressive blood cancer, is the most common type of acute leukemia in adults and most often develops when myeloid cells that normally develop into the various types of mature blood cells instead form abnormal myeloblasts.
Advertisement
In a phase 1 trial presented at ASH 2024, clinical benefit was observed in 100% of patients receiving LYT-200 monotherapy.
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
Quizartinib is a novel, second-generation, selective type II FLT3 inhibitor approved in the US for FLT3-ITD–positive AML.
QuANTUM-Wild has begun treatment administration in patients with newly-diagnosed FLT3-ITD+ AML.
Moderated by Amer M. Zeidan, MBBS, a panel discusses the critical roles of patient fitness, genetics in AML treatment.
This expert panel shares insights into the latest advancements, clinical challenges in AML and more.
Advertisement
Gain valuable insights from leading experts as they explore how targeted therapies are shaping the future of AML management.
Investigators looked into how intensified induction therapy impacts survival and MRD negativity in patients with AML.
Results from the phase I/II SAVE study in older and unfit patients with relapsed or refractory acute myeloid leukemia.
HMAs, either as monotherapy or in combination with venetoclax, represent the standard of care for higher-risk MDS or AML.
Phase 2 study results outline benefit of adding venetoclax to intensive chemo in MDS and AML patients.
Ziftomenib, venetoclax, and azacitadine is an close to an all-oral regimen for relapsed/refractory acute leukemias.
The benefit of alternating venetoclax regimens was shown in patients with AML and certain AML subgroups.
The confirmed complete response rate of ziftomenib with chemotherapy was high in patients with AML subtypes.
Interim results suggest acceptable safety and high efficacy of CPX-351 plus ivosidenib.
High complete response rates and low early mortality rates facilitate the majority of patients to allogeneic SCT.
What potential does ASTX727 have in MDS and AML treatment?
New research is offering new hope for these challenging case of MDS and sAML.
The approval is based on results of the phase I/II AUGMENT-101 trial, where revumenib achieved a CR+CRh rate of 21%.
On this episode, Andrew Wei, MBBS, PhD, goes especially in depth regarding venetoclax plus azacitidine combination.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.